Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9435439 | 0.87 | L3MBTL1 (0.42) | CYP1A2CYP2C19ALDH1A1CPA3NAALAD2 | |
| SCHEMBL3263344 | 0.86 | TBXAS1 (0.51) | CYP2D6CYP1A2CYP2C19ALDH1A1TSHR | |
| SCHEMBL1595458 | 0.86 | TBXAS1 (0.51) | CYP2D6CYP1A2CYP2C19ALDH1A1TSHR | |
| SCHEMBL7980726 | 0.86 | KMT2A (0.55) | CYP2D6CYP1A2CYP2C19ALDH1A1TSHR | |
| SCHEMBL9541921 | 0.84 | USP5 (0.51) | CYP2D6CYP1A2SMN1; SMN2FFAR1KDM4E | |
| SCHEMBL10587417 | 0.84 | MMP8 (0.50) | TSHRCHRM1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL9541600 | 0.84 | CYP2C9 (0.44) | CYP2D6CYP1A2CYP2C19ALDH1A1TSHR | |
| SCHEMBL2303442 | 0.82 | KMT2A (0.49) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL652523 | 0.82 | CYP2C19 (0.53) | CYP2D6CYP1A2CYP2C19ALDH1A1TSHR | |
| SCHEMBL27491825 | 0.82 | CYP2C19 (0.53) | CYP2D6CYP1A2CYP2C19ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4201922-A1 | METHOD FOR PURIFYING WASTED SOLUTION COMPRISING N-METHYL-2-PYRROLIDONE | JAEWON INDUSTRIAL CO., LTD (KR) | 2023-06-28 | — | — | EP | claimed |
| US-20230192609-A1 | METHOD FOR PURIYFING WASTE N-METHYL-2-PYRROLIDONE | JAEWON INDUSTRIAL CO., LTD (KR) | 2023-06-22 | — | — | US | claimed |
| US-20180277766-A1 | THERMALLY ACTIVATED DELAYED FLUORESCENCE ORGANIC LIGHT EMITTING DIODE HAVING HOST MATRIX POLARITY CO-DOPING | DOW GLOBAL TECHNOLOGIES LLC | 2018-09-27 | — | — | US | claimed |
| US-9403951-B2 | Flame-retardant polyester | ETERNAL MATERIALS CO., LTD. (TW) | 2016-08-02 | — | — | US | claimed |
| US-20150291740-A1 | FLAME-RETARDANT POLYESTER | ETERNAL MATERIALS CO., LTD. (TW) | 2015-10-15 | — | — | US | claimed |
| EP-1877483-B1 | METHOD FOR PRODUCING CURE SYSTEM, ADHESIVE SYSTEM, AND ELECTRONIC DEVICE | MOMENTIVE PERFORMANCE MAT INC (US) | 2013-05-08 | — | — | EP | claimed |
| EP-2264097-B1 | Method for producing cure system, adhesive system, and electronic device | MOMENTIVE PERFORMANCE MAT INC (US) | 2013-05-08 | — | — | EP | claimed |
| US-20120283089-A1 | ZIEGLER-NATTA CATALYST FOR OLEFIN POLYMERIZATION | HYOSUNG CORPORATION (KR) | 2012-11-08 | — | — | US | claimed |
| EP-2520594-A2 | ZIEGLER-NATTA CATALYST FOR OLEFIN POLYMERIZATION | Hyosung Corporation (KR) | 2012-11-07 | — | — | EP | claimed |
| US-20120171397-A1 | Keto Acid Esters As PVC Plasticizers | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-07-05 | — | — | US | claimed |
| EP-1276165-A1 | Nonaqueous secondary cell | Japan Storage Battery Co., Ltd. (JP) | 2003-01-15 | — | — | EP | claimed |
| US-6500933-B1 | STABILIZATION OF GLYCOPROTEINS SUCH AS LIPASE OR OXIDASE VIA CRYSTALLIZATION AND CARBOHYDRATE-TO-CARBOHYDRATE CROSSLINKING WITHIN THE CRYSTAL LATTICE, USING TWO DIFFERENT CROSSLINKING AGENTS; VARIOUS MEDICAL, COSMETIC AND INDUSTRIAL USES | ALTUS BIOLOGICS INC. | 2002-12-31 | — | — | US | claimed |
| US-20020137899-A1 | Crosslinked through one or more carbohydrate moieties in said glycoprotein; storage stability, chemical stability over wider range of conditions while retaining bioactivity in use | ALTUS BIOLOGICS INC. | 2002-09-26 | — | — | US | claimed |
| US-6359118-B2 | STABLITY; USEFUL IN DRUGS, VACCINES, PERSONAL CARE/COSMETICS, VETERINARY DRUGS/VACCINES, FOODS, FEEDS, DIAGNOSTICS, CLEANING AGENTS (DETERGENTS AND DECONTAMINANTS); CATALYTIC AND BINDING COMPONENTS OF BIOSENSORS | ALTUS BIOLOGIES, INC. | 2002-03-19 | — | — | US | claimed |
| US-20010008934-A1 | CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS | ALTHEA TECHNOLOGIES, INC. | 2001-07-19 | — | — | US | claimed |
| US-6180739-B1 | CYCLODEXTRINS WITH ACRYLATE AND ANHYDRIDES | AMERICAN DENTAL ASSOCIATION HEALTH FOUNDATION | 2001-01-30 | — | — | US | claimed |
| EP-1009759-A1 | CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS | Altus Biologics Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| US-5929131-A | Polymerizable cyclodextrin derivatives | AMERICAN DENTAL ASSOCIATION HEALTH FOUNDATION (US) | 1999-07-27 | — | — | US | claimed |
| WO-1999012959-A1 | CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS | ALTUS BIOLOGICS INC. (US) | 1999-03-18 | — | — | WO | claimed |
| US-5792821-A | Polymerizable cyclodextrin derivatives | AMERICAN DENTAL ASSOCIATION HEALTH FOUNDATION (US) | 1998-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192609-A1 | METHOD FOR PURIYFING WASTE N-METHYL-2-PYRROLIDONE | NPEPPS, AZI2, ALKBH2 | CYP2D6 2671/4885CYP1A2 1416/4885CYP2C19 2123/4885 |
| US-20120171397-A1 | Keto Acid Esters As PVC Plasticizers | KDM7A, FFAR2, KDM4A | CYP2D6 1190/4885CYP1A2 562/4885CYP2C19 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.